Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure

Medicine and Dentistry

• Overall Survival 100%
• Molecularly Targeted Therapy 100%
• Protein Tyrosine Kinase 100%
• Gamma Urogastrone 100%
• Epidermal Growth Factor Receptor 2 100%
• Hope 100%
• Cytotoxic Chemotherapy 100%
• Biological Marker 50%
• Cell Survival 50%
• Screening 50%
• Vasculotropin 50%
• Gene Expression Profiling 50%
• Mechanistic Target of Rapamycin 50%
• Biological Product 50%
• Epidermal Growth Factor Receptor 50%
• Gefitinib 50%
• Cancer Cell 50%
• Inositol 50%
• Drug Efficacy 50%
• Bevacizumab 50%
• Trastuzumab 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Cytotoxic Chemotherapy 100%
• Overall Survival 100%
• Epidermal Growth Factor Receptor 2 100%
• Gamma Urogastrone 100%
• Protein Tyrosine Kinase 100%
• Biological Marker 50%
• Vasculotropin 50%
• Bevacizumab 50%
• Gefitinib 50%
• Biological Product 50%
• Inositol 50%
• Lapatinib 50%
• Scatter Factor Receptor 50%
• Mammalian Target of Rapamycin 50%
• Epidermal Growth Factor Receptor 50%
• Erlotinib 50%
• Trastuzumab 50%
• Fibroblast Growth Factor Receptor 50%

Biochemistry, Genetics and Molecular Biology

• Hope 100%
• Epidermal Growth Factor Receptor 100%
• Overall Survival 66%
• Receptor Tyrosine Kinase 66%
• Gene Expression Profiling 33%
• Anticancer 33%
• Cancer Cell 33%
• Erlotinib 33%
• Screening 33%
• Cell Survival 33%
• Drug Efficacy 33%
• Gefitinib 33%
• Vascular Endothelial Growth Factor 33%
• Hepatocyte Growth Factor 33%
• Mechanistic Target of Rapamycin 33%
• Bevacizumab 33%
• Trastuzumab 33%
• Growth Factor Receptor 33%
• Fibroblast Growth Factor Receptor 33%
• Inositol 33%